Skip to main content

Table 3 Analysis endpoints and side effects during first year of protocol therapy according to treatment assignment

From: Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

   

Treatment

 

Overall

Exemestane + OFS

Tamoxifen + OFS

 

(n = 1967a)

(n = 987)

(n = 980)

Analysis endpoint

 Early-onset hot flashes/sweating, grade ≥2

 

848 (43)

411 (42)

437 (45)

 Early-onset musculoskeletal symptoms, grade ≥2

 

516 (26)

331 (34)

185 (19)

Side effect and time point

Grade

   

Hot flashes

 Baseline

Unk

2 (0)

2 (0)

0 (0)

Gr0

1812 (92)

924 (94)

888 (91)

Gr1

134 (7)

51 (5)

83 (8)

Gr2

19 (1)

10 (1)

9 (1)

 3 months

Unk

8 (0)

3 (0)

5 (1)

Gr0

637 (32)

325 (33)

312 (32)

Gr1

766 (39)

386 (39)

380 (39)

Gr2

500 (25)

248 (25)

252 (26)

Gr3

56 (3)

25 (3)

31 (3)

 6 months

Unk

20 (1)

9 (1)

11 (1)

Gr0

525 (27)

294 (30)

231 (24)

Gr1

797 (41)

401 (41)

396 (40)

Gr2

573 (29)

260 (26)

313 (32)

Gr3

52 (3)

23 (2)

29 (3)

Sweating

 Baseline

Unk

3 (0)

3 (0)

0 (0)

Gr0

1832 (93)

920 (93)

912 (93)

Gr1

119 (6)

56 (6)

63 (6)

Gr2

13 (1)

8 (1)

5 (1)

 3 months

Unk

9 (0)

4 (0)

5 (1)

Gr0

1332 (68)

675 (68)

657 (67)

Gr1

444 (23)

219 (22)

225 (23)

Gr2

182 (9)

89 (9)

93 (9)

 6 months

Unk

22 (1)

9 (1)

13 (1)

Gr0

1285 (65)

688 (70)

597 (61)

Gr1

447 (23)

206 (21)

241 (25)

Gr2

213 (11)

84 (9)

129 (13)

Musculoskeletal symptoms

 Baseline

Unk

3 (0)

3 (0)

0 (0)

Gr0

1669 (85)

837 (85)

832 (85)

Gr1

248 (13)

125 (13)

123 (13)

Gr2

47 (2)

22 (2)

25 (3)

Gr3

0 (0)

0 (0)

0 (0)

 3 months

Unk

9 (0)

5 (1)

4 (0)

Gr0

1360 (69)

670 (68)

690 (70)

Gr1

467 (24)

231 (23)

236 (24)

Gr2

118 (6)

74 (7)

44 (4)

Gr3

13 (1)

7 (1)

6 (1)

 6 months

Unk

21 (1)

9 (1)

12 (1)

Gr0

1070 (54)

463 (47)

607 (62)

Gr1

648 (33)

366 (37)

282 (29)

Gr2

198 (10)

128 (13)

70 (7)

Gr3

30 (2)

21 (2)

9 (1)

 9 months

Unk

41 (2)

24 (2)

17 (2)

Gr0

995 (51)

386 (39)

609 (62)

Gr1

670 (34)

392 (40)

278 (28)

Gr2

228 (12)

159 (16)

69 (7)

Gr3

33 (2)

26 (3)

7 (1)

 12 months

Unk

37 (2)

23 (2)

14 (1)

Gr0

965 (49)

388 (39)

577 (59)

Gr1

708 (36)

400 (41)

308 (31)

Gr2

235 (12)

158 (16)

77 (8)

Gr3

22 (1)

18 (2)

4 (0)

  1. Reports of hot flashes and sweating side effects and of musculoskeletal symptoms according to common terminology criteria for adverse events (CTCAE) v3.0 at time points during the first year of protocol therapy. All data are summarized as number (%) of patients. aPatients without any adverse event data (two patients without hot flashes/sweating and one without musculoskeletal symptoms) were excluded from summary. Unk unknown, Gr grade OFS ovarian function suppression